Transaction DateRecipientSharesTypePriceValue
2nd November 2020Adam K Stern619Open or private purchase$0.00
2nd October 2020Adam K Stern619Open or private purchase$0.00
30th September 2020Matthew Wikler20,725Grant/award etc.$0.00
17th September 2020Eric J Ende17,000Open or private purchase$5.79$98,375.60
3rd September 2020Adam K Stern639Open or private purchase$6.66$4,255.74
1st September 2020Patrick G Lepore38,986Grant/award etc.$0.00
21st August 2020Adam K Stern20,000Open or private purchase$0.83$16,600.00
13th August 2020Eric J Ende1,200Open or private purchase$7.74$9,288.00
13th August 2020Eric J Ende3,800Open or private purchase$7.80$29,640.00
12th August 2020Eric J Ende15,000Open or private purchase$7.76$116,355.00
Matinas Bio Pharma Holdings
Matinas Bio Pharma Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B. The company was founded in May 2013 and is headquartered in Bedminster, NJ.


Ticker: MTNB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1582554
Employees: 21
Exchange: NYSE American
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $15 M (0%)
Marketable Securities, Current: $53 M (0%)
Assets, Current: $69 M (131%)
Property, Plant and Equipment, Net: $2 M (-6%)
Assets: $79 M (96%)
Accounts Payable, Current: $495 Th (-27%)
Accrued Liabilities, Current: $1 M (-26%)
Liabilities, Current: $2 M (-22%)
Liabilities: $6 M (-12%)
Common Stock, Value, Issued: $20 Th (21%)
Common Stock, Shares, Issued: $199 M (21%)
Retained Earnings (Accumulated Deficit): $96 M (13%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $478 Th (54184%)
Liabilities and Equity: $79 M (96%)
Revenue: $90 Th (0%)
Research and Development: $3 M (-54%)
General and Administrative Expenses: $2 M (-48%)
Operating Income/Loss: $6 M (-52%)